additional information to large buys13 Sep 2022 12:34
I am responsible for a 100k & 10 k buy this morning.
I am NOT in receipt of any information from the company or was I motivated by other large buys.
I was motivated by a n RNS by Vela Tech Plc an investment company that is a shareholder of SGSC ( St Georges Street Capital ).
The company RNS is Vela they are extremely positive in the AZD1656, and St Georges are actively promoting the drug.
This was dated 8th August,2022 , I do believe in another two months we will have positive news concerning the above drug. ( My time scales are normally bang on target due to other research I do).
Please see the press release below, concerning our drug AZD1656.
Update re. St George Street Capital Ltd
Lancet Review for ARCADIA Phase 2 Clinical Trial
The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that St George Street Capital Ltd ("SGSC"), has today announced the publication in Lancet eClinicalMedicine of details of the ARCADIA clinical trial which investigated AZD1656 for people with diabetes and COVID-19.
Vela holds an economic interest in the commercialisation of AZD1656, details of which were included in the announcement published by Vela on 20 October 2020.
Highlights:
· ARCADIA trial investigated AZD1656 for people with diabetes hospitalised with COVID-19.
· Patients in the AZD1656 arm were observed to have lower mortality and AZD1656 was shown to have immunomodulatory capability (as predicted).
· The article in The Lancet, one of the world's leading peer-reviewed medical journals, can be found at https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00334-0/fulltext
· Vela notes the statement from SGSC that 'the evidence presented here suggests that specific activation of Tregs might suppress the inappropriate inflammation which is the prime cause of tissue damage in autoimmune disease.' This reinforces the mode of action will potentially work in a wide range of autoimmune diseases.
· SGSC is continuing to have discussions with potential partners regarding AZD1656.